Abstract |
New vaccines and drug treatments are needed for tackling the neglected diseases ( NDs) of poor countries. These diseases are associated with high levels of mortality and/or morbidity, but lack appropriate vaccines and drug treatments because of bacterial resistance, toxicity, long-treatment protocols, problems with administration or because none are available. Current initiatives directed at research and development (R&D) of NDs are being led predominantly by the governmental, inter-governmental and private not-for-profit sectors implemented by way of public-private partnerships. Push and pull mechanisms targeted at the pharmaceutical industry have also been proposed as another way to stimulate R&D of NDs; however, these should be viewed with some caution. Stimulating R&D for NDs is important as part of a wider long-term public health strategy and must be addressed simultaneously with resolving more immediate problems of access to medicines and health system sustainability in less developed countries.
|
Authors | Monique F Mrazek, Elias Mossialos |
Journal | Health policy (Amsterdam, Netherlands)
(Health Policy)
Vol. 64
Issue 1
Pg. 75-88
(Apr 2003)
ISSN: 0168-8510 [Print] Ireland |
PMID | 12644330
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Infective Agents
- Drugs, Investigational
- Vaccines
|
Topics |
- Anti-Infective Agents
- Developing Countries
- Drug Evaluation
- Drugs, Investigational
- Endemic Diseases
(prevention & control)
- Global Health
- Health Policy
- Health Services Accessibility
- Health Services Needs and Demand
- Humans
- Private Sector
- Public Health Practice
- Public Sector
- Research Support as Topic
- Vaccines
|